Cladis Investment Advisory, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Cladis Investment Advisory, LLC
- $138 Billion
- Q1 2025
A detailed history of Cladis Investment Advisory, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Cladis Investment Advisory, LLC holds 10,000 shares of CPRX stock, worth $249,600. This represents 0.18% of its overall portfolio holdings.
Number of Shares
10,000
Previous 10,000
-0.0%
Holding current value
$249,600
Previous $209 Million
16.2%
% of portfolio
0.18%
Previous 0.15%
Shares
2 transactions
Others Institutions Holding CPRX
# of Institutions
388Shares Held
99.3MCall Options Held
37KPut Options Held
20.5K-
Black Rock Inc. New York, NY18.7MShares$467 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.5MShares$212 Million0.0% of portfolio
-
State Street Corp Boston, MA5.53MShares$138 Million0.01% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.42MShares$85.4 Million2.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.14MShares$78.3 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.57B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...